EVO视讯 EVO真人■

Be the most trusted biotech company

2020-12-17

NMPA Has Accepted The NDA of HLX01(Rituximab Injection) for the Treatment of Rheumatoid Arthritis
2020-12-07

Henlius Adalimumab Biosimilar 汉达远® Approved by NMPA
2020-11-12

The IND Application of Henlius Daratumumab Biosimilar Accepted by NMPA
2020-11-09

First Patient Dosed in Phase 1 Clinical Trial of Henlius Denosumab Biosimilar HLX14
2020-11-06

Henlius ACE2-Fc Fusion Protein HLX71 Received IND Approval from US FDA
2020-10-29

The Results of the Phase 3 Study of Henlius’ Adalimumab Biosimilar HLX03 Presented on EADV 2020
2020-10-15

Henlius and Essex Enter into a Global Co-Development and Exclusive License Agreement, to Jointly Develop Bevacizumab to Treat Ophthalmic Diseases
2020-10-05

Investigational New Drug Application of Henlius SARS-CoV-2 Neutralizing Antibody HLX70 Approved by US FDA
2020-09-30

Henlius Granted Exclusive Development and Commercialisation Rights of HLX02 in the US and Canada to Accord

1
2
3
4